Summary
The product Semaglutide 5 mg, manufactured by EDQ Remedies, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number VTS744, was submitted by EOQ-Shop.com and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the concentration of Semaglutide at 5.09 mg, slightly exceeding the labeled claim of 5 mg. The product’s purity was determined to be 99.250%.
The testing process began on 28 January 2025, with the sample received on 31 January 2025, and analysis completed on 4 February 2025. The results confirm high purity and a slightly higher-than-labeled concentration, indicating a well-formulated product. However, scrutiny of manufacturer-submitted samples remains essential to ensure reliability. Independent third-party testing remains critical to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: EDQ Remedies
- Product Name: Semaglutide 5 mg
- Active Ingredient: Semaglutide
- Batch Number: VTS744
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #57018
- Testing Ordered: 28 January 2025
- Sample Received: 31 January 2025
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: EOQ-Shop.com (Manufacturer)
- Analysis Paid For By: EOQ-Shop.com (Manufacturer)
Testing Results
- Specification: 5 mg (as stated on the label)
- Measured Concentration: 5.09 mg
- Accuracy: 101.8% (1.8% above the label claim)
- Purity: 99.250%
Verification Details
Verification URL: https://janoshik.com/tests/57018_L46S8A5FCVRK
Evaluation of Manufacturer-Submitted Testing
This analysis highlights that the Semaglutide 5 mg sample slightly exceeds its labeled concentration, measuring 5.09 mg instead of 5 mg. While this suggests a potent formulation with high purity, variations in concentration emphasize the importance of stringent quality control. Since EOQ-Shop.com submitted and funded the test, independent validation through third-party testing across multiple batches is recommended to ensure consistent dosing.
Conclusion
The analysis confirms that Semaglutide 5 mg contains a slightly higher concentration than labeled, measuring 5.09 mg, with an exceptionally high purity of 99.250%. While this batch exhibits strong quality control in terms of purity, the minor concentration variation underscores the importance of continued testing to ensure accuracy across different batches. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding peptide products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
